Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Unpaid sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increase in vaccines research and development in developed nations
3.2.1.2 Growing cases of tetanus and diphtheria in some countries
3.2.1.3 Increasing government initiatives programs for vaccination
3.2.1.4 Technological advancemen in development of toxoid vaccine
3.2.2 Industry pitfalls & challenges
3.2.2.1 Side-effects associated with toxoid vaccine
3.3 Growth potential analysis
3.4 Technological landscape
3.5 Regulatory landscape
3.6 Porter’s analysis
3.6.1 Supplier power
3.6.2 Buyer power
3.6.3 Threat of new entrants
3.6.4 Threat of substitutess
3.6.5 Industry rivalry
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Competitive positioning matrix
4.4 Strategic outlook matrix
Chapter 5 Market Estimates and Forecast, By Vaccine Type, 2018 – 2032 ($ Mn)
5.1 Key trends
5.2 Tetanus toxoid (TT)
5.3 Diphtheria and tetanus (DT)
5.4 Tetanus and diphtheria (Td)
5.5 Diphtheria, tetanus, and pertussis (DTaP)
5.6 Tetanus, diphtheria, and pertussis (Tdap)
5.7 Diphtheria, tetanus, pertussis, Hib and hepatitis B (DTP-Hib-HepB)
5.8 Pentavalent (DTaP-IPV/Hib)
5.9 Hexavalent (DTaP-IPV/Hib-HepB)
5.10 Other vaccine types
Chapter 6 Market Estimates and Forecast, By Age Group, 2018 – 2032 ($ Mn)
6.1 Key trends
6.2 Pediatric
6.3 Adult
Chapter 7 Market Estimates and Forecast, By End-Use, 2018 – 2032 ($ Mn)
7.1 Key trends
7.2 Hospitals and clinics
7.3 Government organizations
7.4 Other end-users
Chapter 8 Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)
8.1 Key trends
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Italy
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.5.4 Rest of Latin America
8.6 Middle East and Africa
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Rest of Middle East and Africa
Chapter 9 Company Profiles
9.1 Bharat Biotech International Limited
9.2 Biological E. Limited
9.3 Biological Products Institute (BPI) Argentina
9.4 Chengdu Institute of Biological Products Co., Ltd.
9.5 GlaxoSmithKline
9.6 Johnson & Johnson
9.7 Merck & Co., Inc.
9.8 Mitsubishi Tanabe Pharma Corporation
9.9 Panacea Biotec Limited
9.10 Pfizer Inc.
9.11 Sanofi
9.12 Serum Institute of India
9.13 Zydus Group
